Health TrialsbyHealthPanel

Effect of Indoor Air Quality Improvement on Health in Patients With Interstitial Lung Disease

ConditionILD
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19+
SponsorPeking Union Medical College

About this trial

Air pollution threatens the respiratory health of patients with interstitial lung disease (ILD). High-efficiency air purifiers, featuring easy operation and excellent particulate matter removal efficiency, have been shown in previous studies to potentially delay lung function deterioration and reduce acute exacerbation risk in respiratory disease patients. This randomized crossover study employs air purifiers to filter indoor gaseous pollutants, allergens, and other contaminants, aiming to alleviate respiratory irritation, improve daily life comfort, and enhance overall health status in ILD patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients diagnosed with interstitial lung disease (ILD).

Stable disease status, defined as no hospitalization due to acute exacerbation within the past month.

Disqualifiers

Patients with complications of severe organ failure (including heart, liver, or kidney failure), malignant tumors, or mental disorders.

A history of respiratory tract infection within the past two weeks.

Trial design

Design model

Crossover

Treatments tested in this trial

  • Air Purifier (with Filter) Arm

    Behavioral

    Place an air purifier with high-efficiency filters in the home, and turn it on for at least 18 hours every day.

  • Purifier (without Filter) Arm

    Behavioral

    Place an air purifier without a filter in the home.

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: Purifier (without Filter) ArmSham comparator 1 intervention
Group B: Air Purifier (with Filter) ArmExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Symptom Improvement-related Indicators (e.g., Improvement in Respiratory Symptom Score)

St. George's Respiratory Questionnaire (SGRQ):Score Range:Minimum score: 0 points;Maximum score: 100 points.A higher score indicates worse outcomes for the patient.

Time frame
Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
2

Pulmonary Function Indicators (e.g., Pulmonary Diffusing Capacity)

Time frame
Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
3

Quality of Life Indicators (e.g., CAT Score)

COPD Assessment Test (CAT):It is a short, validated, patient-reported outcome (PRO) tool specifically designed to measure the impact of pulmonary disease on a patient's health status and daily life.Score Range:Minimum score: 0 points;Maximum score: 40 points.A higher score indicates worse health status and greater pulmonary disease-related burden for the patient.

Time frame
Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
4

Blood Sample Indicators (e.g., Concentration of Interleukin-8)

Assessment of Changes in Pulmonary Inflammation or Lung Injury Before and After Intervention Using Concentrations of Biomarkers Such as Interleukin-8

Time frame
Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Peking Union Medical College

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: